[Richard Laing du département Médicaments Essentiels de l'OMS annonce la
publication sur le site web de l'OMS de la publication en anglais du
chapitre sur la pharmacovigilance dans la nouvelle édition de " La Situation
des produits pharmaceutiques dans le monde"
Pour télécharger le chapitre :
http://apps.who.int/medicinedocs/en/m/abstract/Js18771en/
CB]
-----Message d'origine-----
la part de Laing, Richard Ogilvie
Envoyé : mercredi 24 août 2011 14:01
onPharmacovigilance
E-DRUG: New World Medicines Situation Chapter published on Pharmacovigilance
------------------------------------------------------------------------
To All E-Druggers,
I am very pleased to announce the publication of a new World Medicines
Situation chapter on Pharmacovigilance. The chapter was written by Shanthi
Pal from the
Department of Essential Medicines and Pharmaceutical Policies, WHO, Geneva,
Alex Dodoo from the University of Ghana Medical School in Ghana, Aukje
Mantel from Utrecht University in the Netherlands and Sten Olsson from the
Uppsala Monitoring Centre in Sweden. To download the chapter please go to
the URL http://apps.who.int/medicinedocs/en/m/abstract/Js18771en/ that
includes the following abstract.
Pharmacovigilance (PV) aims to improve patient safety through the detection,
assessment, understanding and prevention of adverse effects and other drug
related problems;
- PV, as a discipline, has seen tremendous growth over the past decade, but
in response to different needs and priorities worldwide. While ' high-burden
diseases' have been the focus in some settings, elsewhere this growth has
been driven by a demand for transparency and access to information;
- Recent years have seen a trend towards Good Pharmacovigilance Practice
(GPP), particularly in industrialized countries to assure standards and
innovations in the collection, management, analysis and use of medicine
safety information - with patient safety as the ultimate objective;
- Many resource-limited countries will require additional support (technical
and financial) to build PV capacity to effective levels;
- Despite 40 years of PV, patients worldwide continue to be affected by
preventable harm from medicines. It is important to analyse and learn from
these events;
- For PV to be effective there is a need for timely and responsible
communication of the available evidence, involving all stakeholders;
- Many new PV initiatives are being undertaken. But it is important that
these efforts are not duplicated and that scarce resources are used wisely.
- To download the chapter directly go to
http://apps.who.int/medicinedocs/documents/s18771en/s18771en.pdf
For more information on other chapters go to
http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index
.html or the Table of
Contents at
http://www.who.int/medicines/areas/policy/world_medicines_situation/wmsr_tab
le/en/index.html
Thank you
Richard
Richard Laing (Coordinator)
Medicine Information and Evidence for Policy,
Department of Essential Medicines and Pharmaceutical Policies
World Health Organization
CH-1211 Geneva 27, Switzerland
Tel 41 22 791 4533
Fax 41 22791 4167
E-mail laingr@who.int